×
About 4,188 results

ALLMedicine™ HER2+ Center

Research & Reviews  1,040 results

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)
https://clinicaltrials.gov/ct2/show/NCT04379596

May 20th, 2022 - DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-positive adv...

Systemic management of brain metastases in HER2+ breast cancer in 2022.
https://www.ncbi.nlm.nih.gov/pubmed/35579591
Clinical Advances in Hematology & Oncology : H&O; Alder L, Sammons S et. al.

May 18th, 2022 - Up to half of all patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are associated with reduced overall survival and decreased quality of life. A...

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05378464

May 18th, 2022 - Patients with HER2-positive (HER2+) metastatic breast cancer will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab. Investigators hypothesize these therapies will elicit CD4+ HER2 s...

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05132582

May 17th, 2022 - Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days Trastuzumab and pertuzumab will be administered a...

Fatty acid synthase: a druggable driver of breast cancer brain metastasis.
https://doi.org/10.1080/14728222.2022.2077189
Expert Opinion on Therapeutic Targets; Menendez JA, Lupu R

May 13th, 2022 - Brain metastasis (BrM) is a key contributor to morbidity and mortality in breast cancer patients, especially among high-risk epidermal growth factor receptor 2-positive (HER2+) and triple-negative/basal-like molecular subtypes. Optimal management ...

see more →

Guidelines  1 results

SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma.
https://doi.org/10.1007/s12094-012-0836-9
Clinical & Translational Oncology : Official Publication ... Rivera F, Grávalos C et. al.

Jun 23rd, 2012 - Gastric adenocarcinomas are tumours of decreasing incidence in the Western world, although they are still the fourth leading cause of cancer mortality. The purpose of these clinical guidelines is to provide recommendations for the diagnosis and tr...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  100 results

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)
https://clinicaltrials.gov/ct2/show/NCT04379596

May 20th, 2022 - DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-positive adv...

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05378464

May 18th, 2022 - Patients with HER2-positive (HER2+) metastatic breast cancer will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab. Investigators hypothesize these therapies will elicit CD4+ HER2 s...

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05132582

May 17th, 2022 - Control arm: Placebo given orally twice daily plus trastuzumab and pertuzumab every 21 days Experimental arm: Tucatinib 300 mg given orally twice daily plus trastuzumab and pertuzumab every 21 days Trastuzumab and pertuzumab will be administered a...

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT05319873

May 12th, 2022 - PRIMARY OBJECTIVES: I. To assess the safety of the combination of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer. (Phase 1 Dose Escalation Trial) II. To determine the recommended phase 2 dose of ribociclib ...

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients
https://clinicaltrials.gov/ct2/show/NCT03913234

May 10th, 2022 - This trial is performed in a multicenter, single-group, and phases IB and II clinical trial. This is a single-group clinical trial of the effects of ribociclib, letrozole and trastuzumab in postmenopausal women with HR+, HER2+ advanced breast canc...

see more →

News  525 results

Clinical Edge Journal Scan Commentary: Breast Cancer May 2022
https://www.mdedge.com/hematology-oncology/article/254265/breast-cancer/clinical-edge-journal-scan-commentary-breast-cancer
Erin Roesch, MD

Apr 29th, 2022 - Erin Roesch, MD The phase 2 DESTINY-Breast01 trial showed impressive antitumor activity with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a heavily pretreated patient population with metastatic human epidermal growth factor recept.

Pyrotinib boosts survival in lapatinib-resistant HER2+ breast cancer in the real world
https://www.mdedge.com/hematology-oncology/article/254060/breast-cancer/pyrotinib-boosts-survival-lapatinib-resistant-her2

Apr 25th, 2022 - Key clinical point: Pyrotinib-based therapy could prolong survival in patients with lapatinib-resistant, human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer, including those with brain metastases and those who benefi.

Local therapy remains standard of care for pT1aN0M0 HER2+ breast cancer
https://www.mdedge.com/hematology-oncology/article/254059/breast-cancer/local-therapy-remains-standard-care-pt1an0m0-her2

Apr 25th, 2022 - Key clinical point: In patients with pT1aN0M0, human epidermal growth factor receptor 2 positive (HER2+) invasive breast cancer adding systemic therapy after surgical excision had clinical outcomes similar to local therapy alone. Major finding: Ov.

Trastuzumab deruxtecan bests trastuzumab emtansine in HER2+ metastatic breast cancer
https://www.mdedge.com/hematology-oncology/article/254051/breast-cancer/trastuzumab-deruxtecan-bests-trastuzumab-emtansine

Apr 25th, 2022 - Key clinical point: Trastuzumab deruxtecan was superior to trastuzumab emtansine in reducing the risk for disease progression or death in patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer who had been.

Patient Profile 1: Second-Line Therapy for HER2+ mBC
https://www.onclive.com/view/patient-profile-1-second-line-therapy-for-her2-mbc

Apr 17th, 2022 - Transcript: Neil Iyengar, MD: Let's move on and hear about what happened next. It sounds like she subsequently went on to develop brain metastases. Milana Dolezal, MD, MSci: Unfortunately, she then developed brain metastases. She did come in w...

see more →